Easy Access To GLP-1s Is Causing Big Problems For Obesity Studies
Participants are quitting placebo arms of obesity studies or seeking out commercially available GLP-1 drugs while staying on the trial, causing problems for developers hoping to catch up with the frontrunners.
Scrip - June 15, 2026

Aurobindo Looks To Bolster French Footprint With Facility Purchase
Aurobindo has enhanced its operations in France by acquiring a former Bristol Myers Squibb manufacturing facility through its local Arrow subsidiary.
Generics Bulletin - June 15, 2026

Formycon Started 2026 On A Strong Financial Note – Can It Be Maintained?
With its full-year guidance now confirmed, Formycon's numbers are moving in the right direction after a difficult 2025.
Generics Bulletin - June 15, 2026

EHA 2026: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Scrip - June 15, 2026

Brazil Aligns With Global Consensus On Biosimilar Switching
Anvisa says biosimilar switching can be done safely under approved conditions, aligning Brazil with international regulators while stressing monitoring, traceability and safeguards against unplanned changes.
Generics Bulletin - June 15, 2026

Generics Pricing Pact Gives Canada Two More Years
Canada’s pCPA and CGPA have extended their national generic-drug pricing framework to 2028, preserving cost-control measures, price predictability and supply certainty for medicines reimbursed by public drug plans.
Generics Bulletin - June 15, 2026

EHA 2026: Legend Impresses With Early In Vivo CAR-T Results In Lymphoma
Already a leader in traditional CAR-Ts, Legend is moving fast with its in vivo platform.
Scrip - June 15, 2026

The Socio-Economic Case For Prevention, With Deloitte’s Elizabeth Hampson
In this episode of the Over the Counter Podcast, HBW Insight talks to Deloitte's Elizabeth Hampson about the growing role of self-care in prevention, where OTC, VMS and digital health fit, and why health literacy is the biggest opportunity for consumer health companies.
HBW Insight - June 15, 2026

‘The Rules Of The Market Are Changing’ – How Generation Z Will Reshape Consumer Health
Gen Z is upending the consumer health market, demanding transparency and proven efficacy from both OTCs and supplements. Porsche Consulting’s Dr. Roman Hipp warns that companies failing to adapt risk missing out on the growth opportunity presented by this increasingly influential demographic.
HBW Insight - June 15, 2026

Medtech’s AI Literacy Problem Is Also A Manufacturer Liability Problem
Watered-down and imprecise AI training obligations for users of medtech in the EU come at a time when doctors are most in need of new skills.
In Vivo - June 15, 2026

ADA 2026: Lilly And Novo Hold The Line, But The Challengers Are Coming
Lilly's retatrutide matched bariatric surgery weight loss results at ADA 2026, while a diverse challenger field in injectables, oral therapies and novel mechanisms is closing fast.
In Vivo - June 15, 2026

The New AI Trust Moat: How Medical Societies Are Becoming Gatekeepers Of Clinical Intelligence
From ASCO to the AMA, physician organizations are asserting ownership over how their guidelines appear in AI systems—turning clinical knowledge into a controlled, licensable asset and redrawing the competitive map for health-tech companies.
Medtech Insight - June 15, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Lilly explores Zepbound in autoimmune disorders; AstraZeneca pursues interconnected strategy in CVRM; AstraZeneca moving oral GLP-1 into Phase III; Boehringer pursues quality weight loss with survodutide; and GSK scales oncology ambitions with Nuvalent buy.
Scrip - June 15, 2026

Latest FTC Target Of False Supplement Ad Claims Complaint Alleged To Be Repeat Offender
“Amare’s misconduct is particularly egregious” because its “leadership has included two key players already subject to prior court-ordered permanent injunctions prohibiting them from making false, misleading, or unsubstantiated claims,” according to FTC complaint.
HBW Insight - June 15, 2026